Product analysis
Hawthorn 300 mg is an affordable, focused herbal option intended for heart-related support. Differing quantity declarations make it harder to compare the serving with clearly described hawthorn extracts.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
Flavonoids are identified, but the preparation’s comparative quality remains uncertain. A generic hawthorn amount does not establish equivalence to a specific, well-defined extract.
Ingredient Transparency100
The hawthorn amount and flavonoid preparation are stated. Differing quantity declarations do not support assuming a single combined serving amount.
Value For Money100
The labeled serving has a low cost. The unclear combined amount limits how precisely that cost can be compared with other extracts.
Customer Satisfaction82
Customer ratings are generally positive across more than a thousand ratings. The feedback describes satisfaction without establishing effectiveness or safety.
Product Focus73
The single-herb formula has a clear heart-related purpose. Routine benefits remain uncertain because findings for specific hawthorn extracts do not automatically apply to this preparation.
- Format
Capsule - Container
- 90 Capsule(s)
- Per serving
- $0.17
- Customer rating
- 4.6 · 1,573 ratings
Goals
Hawthorn has been studied in specific standardized preparations in clinical heart failure, with conflicting evidence. Those results do not establish a cardiac-tonic effect or routine prevention benefit for this declaration. The amount receives a partial contribution in the saved comparison, but generic hawthorn mass does not establish equivalence to the clinical extracts.
How this product is rated for Heart Health
Ingredient fit88
Goal fit
Dose adequacy
Pathways17
Depth
Breadth
Evidence66
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Hawthorn receives a vascular contribution in the saved finding, but its routine cardiovascular benefit remains uncertain. The supplied clinical evidence concerns a specific WS 1442 extract in treated heart failure and did not significantly improve the primary cardiac-event outcome. A generic 465 mg per serving declaration does not establish that preparation, its composition or comparable benefit.
How this product is rated for Cardiovascular Support
Ingredient fit88
Goal fit
Dose adequacy
Pathways47
Depth
Breadth
Evidence81
Evidence strength
Studied preparation
Formulation logic100
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Hawthorn (leaf and flower) extract (Flavonoids) | 300 mg | |
Hawthorn | 165 mg |
How this ingredient is rated
Composition and Label Disclosure56
Marker and Preparation Disclosure
Species Name Disclosure
Composition and Label Disclosure
Commercial Price and Usability100
Commercial Price per Labeled Serving
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- Real world effectiveness of Hawthorn special extract WS 1442 in a retrospective cohort study from Germany.
- Hawthorn (Crataegus spp.) Clinically Significantly Reduces Blood Pressure in Hypertension: A Meta-Analysis of Randomized Placebo-Controlled Clinical Trials.
- A randomised double blind placebo controlled clinical trial of a standardised extract of fresh Crataegus berries (Crataegisan) in the treatment of patients with congestive heart failure NYHA II.
- [Crataegus Special Extract WS 1442. Assessment of objective effectiveness in patients with heart failure (NYHA II)].
- Prospective, comparative cohort studies and their contribution to the benefit assessments of therapeutic options: heart failure treatment with and without Hawthorn special extract WS 1442.
- [Actions of standardized extracts of Crataegus berries on exercise tolerance and quality of life in patients with congestive heart failure].
- Hawthorn extract for treating chronic heart failure: meta-analysis of randomized trials.
- Clinical efficacy of crataegus extract WS 1442 in congestive heart failure NYHA class II.
- Baseline severity but not gender modulates quantified Crataegus extract effects in early heart failure--a pooled analysis of clinical trials.